Adrenomedullin, a new peptide, in patients with insulinoma

Eur J Endocrinol. 2001 May;144(5):517-20. doi: 10.1530/eje.0.1440517.

Abstract

Background: It has been demonstrated that adrenomedullin, a newly discovered peptide, affects the release of insulin from pancreatic islets cells, suggesting a role in the insulin-regulating system.

Objective: To investigate whether adrenomedullin secretion is modified in patients with insulin-secreting islet cell tumours.

Design: The study was performed in nine patients with surgically treated insulinoma. Circulating adrenomedullin was assayed using a specific radioimmunoassay and its localization and distribution in the tumour were determined by means of immunohistochemistry.

Results: Adrenomedullin concentrations were significantly greater in patients with insulinoma (6.6 +/- 3.2 fmol/ml) than in controls (2.1 +/- 1.1 fmol/ml). In six patients monitored before and after surgery, plasma adrenomedullin decreased from 6.3 +/- 2.9 fmol/ml to 3.0 +/- 1.6 fmol/ml. Immunoreactive adrenomedullin was localized exclusively in the tumours cells, whereas stroma, surrounding pancreas parenchyma and major ducts were negative for the peptide.

Conclusions: Our findings indicate that circulating adrenomedullin is increased in insulinoma and that this increase is related to the neoplastic phenotype.

Publication types

  • Clinical Trial

MeSH terms

  • Adenoma, Islet Cell / metabolism
  • Adenoma, Islet Cell / pathology
  • Adrenomedullin
  • Adult
  • Blood Glucose / metabolism
  • Female
  • Humans
  • Immunohistochemistry
  • Insulin / blood
  • Insulinoma / metabolism*
  • Insulinoma / pathology
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / pathology
  • Peptides / metabolism*

Substances

  • Blood Glucose
  • Insulin
  • Peptides
  • Adrenomedullin